J Mateo1, V Moreno1, A Gupta2, S B Kaye1, E Dean3, M R Middleton2, M Friedlander4, C Gourley5, R Plummer6, G Rustin7, C Sessa8, K Leunen9, J Ledermann10, H Swaisland11, A Fielding11, W Bannister12, S Nicum2, L R Molife13. 1. Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Downs Road, Sutton, SM2 5PT, UK. 2. Department of Oncology, University of Oxford, Oxford, UK. 3. Clinical Trials Unit, The Christie NHS Foundation Trust/University of Manchester, Manchester, UK. 4. Prince of Wales Clinical School, University of New South Wales, Prince of Wales Hospital, Randwick, Australia. 5. University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, UK. 6. Northern Centre for Cancer Care, Newcastle-upon-Tyne, UK. 7. Mount Vernon Hospital, Northwood, UK. 8. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. 9. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium. 10. UCL Hospitals and UCL Cancer Institute, London, UK. 11. AstraZeneca, Macclesfield, UK. 12. PHASTAR, London, UK. 13. Drug Development Unit, The Royal Marsden/The Institute of Cancer Research, Downs Road, Sutton, SM2 5PT, UK. maria.bynoe@icr.ac.uk.
Abstract
BACKGROUND:Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation. PATIENTS AND METHODS: Two stages of sequentially enrolled cohorts: stage 1, pharmacokinetic properties of tablet and capsule formulations were compared in patients with advanced solid tumours; stage 2, tablet dose escalation with expansion cohorts at doses/schedules of interest in patients with solid tumours and BRCAm breast/ovarian cancers. RESULTS:Olaparib 200 mg tablets displayed similar Cmax,ss, but lower AUCss and Cmin,ss than 400 mg capsules. Following multiple dosing, steady-state exposure with tablets ≥300 mg matched or exceeded that of 400 mg capsules. After dose escalation, while 400 mg twice daily was the tablet maximum tolerated dose based on haematological toxicity, 65 % of patients in the randomized expansion phase eventually required dose reduction to 300 mg. Intermittent tablet administration did not significantly improve tolerability. Tumour shrinkage was similar for 300 and 400 mg tablet and 400 mg capsule cohorts. CONCLUSIONS: The recommended monotherapy dose of olaparib tablet for Phase III trials was 300 mg twice daily, simplifying drug administration from 16 capsules to four tablets per day. CLINICAL TRIAL NUMBER: NCT00777582 (ClinicalTrials.gov).
RCT Entities:
BACKGROUND:Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation. PATIENTS AND METHODS: Two stages of sequentially enrolled cohorts: stage 1, pharmacokinetic properties of tablet and capsule formulations were compared in patients with advanced solid tumours; stage 2, tablet dose escalation with expansion cohorts at doses/schedules of interest in patients with solid tumours and BRCAm breast/ovarian cancers. RESULTS:Olaparib 200 mg tablets displayed similar Cmax,ss, but lower AUCss and Cmin,ss than 400 mg capsules. Following multiple dosing, steady-state exposure with tablets ≥300 mg matched or exceeded that of 400 mg capsules. After dose escalation, while 400 mg twice daily was the tablet maximum tolerated dose based on haematological toxicity, 65 % of patients in the randomized expansion phase eventually required dose reduction to 300 mg. Intermittent tablet administration did not significantly improve tolerability. Tumour shrinkage was similar for 300 and 400 mg tablet and 400 mg capsule cohorts. CONCLUSIONS: The recommended monotherapy dose of olaparib tablet for Phase III trials was 300 mg twice daily, simplifying drug administration from 16 capsules to four tablets per day. CLINICAL TRIAL NUMBER: NCT00777582 (ClinicalTrials.gov).
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Stan B Kaye; Jan Lubinski; Ursula Matulonis; Joo Ern Ang; Charlie Gourley; Beth Y Karlan; Amit Amnon; Katherine M Bell-McGuinn; Lee-May Chen; Michael Friedlander; Tamar Safra; Ignace Vergote; Mark Wickens; Elizabeth S Lowe; James Carmichael; Bella Kaufman Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Panagiotis A Konstantinopoulos; Dimitrios Spentzos; Beth Y Karlan; Toshiyasu Taniguchi; Elena Fountzilas; Nancy Francoeur; Douglas A Levine; Stephen A Cannistra Journal: J Clin Oncol Date: 2010-06-14 Impact factor: 44.544
Authors: Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael Journal: Lancet Date: 2010-07-06 Impact factor: 79.321
Authors: Nuala McCabe; Nicholas C Turner; Christopher J Lord; Katarzyna Kluzek; Aneta Bialkowska; Sally Swift; Sabrina Giavara; Mark J O'Connor; Andrew N Tutt; Małgorzata Z Zdzienicka; Graeme C M Smith; Alan Ashworth Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday Journal: Nature Date: 2005-04-14 Impact factor: 69.504
Authors: Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono Journal: N Engl J Med Date: 2009-06-24 Impact factor: 91.245
Authors: Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare L Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Brian Dougherty; Maria Orr; Darren Hodgson; J Carl Barrett; Ursula Matulonis Journal: Lancet Oncol Date: 2014-05-31 Impact factor: 41.316
Authors: Christian Rolfo; Judith de Vos-Geelen; Nicolas Isambert; L Rhoda Molife; Jan H M Schellens; Jacques De Grève; Luc Dirix; Peter Grundtvig-Sørensen; Guy Jerusalem; Karin Leunen; Morten Mau-Sørensen; Ruth Plummer; Maria Learoyd; Wendy Bannister; Anitra Fielding; Alain Ravaud Journal: Clin Pharmacokinet Date: 2019-09 Impact factor: 6.447
Authors: Jung-Min Lee; Cody J Peer; Minshu Yu; Lauren Amable; Nicolas Gordon; Christina M Annunziata; Nicole Houston; Andrew K L Goey; Tristan M Sissung; Bernard Parker; Lori Minasian; Victoria L Chiou; Robert F Murphy; Brigitte C Widemann; William D Figg; Elise C Kohn Journal: Clin Cancer Res Date: 2016-09-23 Impact factor: 12.531
Authors: Christian Rolfo; Nicolas Isambert; Antoine Italiano; L Rhoda Molife; Jan H M Schellens; Jean-Yves Blay; Thomas Decaens; Rebecca Kristeleit; Olivier Rosmorduc; Regina Demlova; Myung-Ah Lee; Alain Ravaud; Katerina Kopeckova; Maria Learoyd; Wendy Bannister; Gershon Locker; Judith de Vos-Geelen Journal: Br J Clin Pharmacol Date: 2020-04-05 Impact factor: 4.335